{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:01:17Z","timestamp":1784613677496,"version":"3.55.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/16\/72\/32270"],"award-info":[{"award-number":["FS\/16\/72\/32270"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.hfc.2021.07.012","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T08:48:15Z","timestamp":1634892495000},"page":"9-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["The Risk of Sudden Death in Children with Hypertrophic Cardiomyopathy"],"prefix":"10.1016","volume":"18","author":[{"given":"Gabrielle","family":"Norrish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Kaski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"39","key":"10.1016\/j.hfc.2021.07.012_bib1","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.hfc.2021.07.012_bib2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/oxfordjournals.aje.a009291","article-title":"Epidemiology of idiopathic cardiomyopathies in children and adolescents. A nationwide study in Finland","volume":"146","author":"Arola","year":"1997","journal-title":"Am J Epidemiol"},{"issue":"17","key":"10.1016\/j.hfc.2021.07.012_bib3","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJMoa021737","article-title":"The epidemiology of childhood cardiomyopathy in Australia","volume":"348","author":"Nugent","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.hfc.2021.07.012_bib4","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa021715","article-title":"The incidence of pediatric cardiomyopathy in two regions of the United States","volume":"348","author":"Lipshultz","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.hfc.2021.07.012_bib5","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/eurheartj\/ehy798","article-title":"Clinical presentation and survival of childhood hypertrophic cardiomyopathy: a retrospective study in United Kingdom","volume":"40","author":"Norrish","year":"2019","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.hfc.2021.07.012_bib6","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1161\/CIRCGENETICS.108.821314","article-title":"Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy","volume":"2","author":"Kaski","year":"2009","journal-title":"Circ Cardiovasc Genet"},{"issue":"9","key":"10.1016\/j.hfc.2021.07.012_bib7","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1161\/CIRCULATIONAHA.104.530303","article-title":"Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study","volume":"112","author":"Nugent","year":"2005","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.hfc.2021.07.012_bib8","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1161\/CIRCULATIONAHA.106.621185","article-title":"Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry","volume":"115","author":"Colan","year":"2007","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.hfc.2021.07.012_bib9","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa075463","article-title":"Shared genetic causes of cardiac hypertrophy in children and adults","volume":"358","author":"Morita","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.hfc.2021.07.012_bib10","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1093\/eurheartj\/ehab148","article-title":"Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy","volume":"42","author":"Marston","year":"2021","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.012_bib11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0002-9149(01)01640-X","article-title":"Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy","volume":"88","author":"Varnava","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hfc.2021.07.012_bib12","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.yjmcc.2017.12.002","article-title":"Hypertrophic cardiomyopathy-linked mutation in troponin T causes myofibrillar disarray and pro-arrhythmic action potential changes in human iPSC cardiomyocytes","volume":"114","author":"Wang","year":"2018","journal-title":"J\u00a0Mol Cell Cardiol"},{"issue":"9","key":"10.1016\/j.hfc.2021.07.012_bib13","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1161\/01.CIR.92.9.2565","article-title":"Primary ventricular fibrillation is associated with increased paced right ventricular electrogram fractionation","volume":"92","author":"Saumarez","year":"1995","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.hfc.2021.07.012_bib14","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jamacardio.2019.2861","article-title":"Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids)","volume":"4","author":"Norrish","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.012_bib15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1161\/CIRCULATIONAHA.120.047235","article-title":"A\u00a0Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy","volume":"142","author":"Miron","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.hfc.2021.07.012_bib16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0735-1097(88)90181-7","article-title":"Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy","volume":"11","author":"McKenna","year":"1988","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.hfc.2021.07.012_bib17","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/adc.59.10.971","article-title":"Hypertrophic cardiomyopathy: an important cause of sudden death","volume":"59","author":"McKenna","year":"1984","journal-title":"Arch Dis Child"},{"issue":"9","key":"10.1016\/j.hfc.2021.07.012_bib18","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/eurheartj\/ehn122","article-title":"Age- and gender-specific mortality rates in childhood hypertrophic cardiomyopathy","volume":"29","author":"Ostman-Smith","year":"2008","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.hfc.2021.07.012_bib19","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1161\/CIRCULATIONAHA.117.030437","article-title":"International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM)","volume":"137","author":"O'Mahony","year":"2018","journal-title":"Circulation"},{"issue":"30","key":"10.1016\/j.hfc.2021.07.012_bib20","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/eurheartj\/eht439","article-title":"A\u00a0novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD)","volume":"35","author":"O'Mahony","year":"2014","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.hfc.2021.07.012_bib21","first-page":"1813","article-title":"A\u00a0cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose beta-adrenoceptor antagonist treatment","volume":"34","author":"Ostman-Smith","year":"1999","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.012_bib22","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/hrt.2006.094730","article-title":"Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy","volume":"93","author":"Kaski","year":"2007","journal-title":"Heart"},{"issue":"14","key":"10.1016\/j.hfc.2021.07.012_bib23","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2013.01.037","article-title":"Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy","volume":"61","author":"Maron","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.hfc.2021.07.012_bib24","first-page":"e533","article-title":"2020 AHA\/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.012_bib25","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/europace\/euaa307","article-title":"Clinical outcomes and programming strategies of implantable cardioverter-defibrillator devices in paediatric hypertrophic cardiomyopathy: a UK National Cohort Study","volume":"23","author":"Norrish","year":"2020","journal-title":"Europace"},{"issue":"7","key":"10.1016\/j.hfc.2021.07.012_bib26","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s00246-013-0676-6","article-title":"Implanted defibrillators in young hypertrophic cardiomyopathy patients: a multicenter study","volume":"34","author":"Kamp","year":"2013","journal-title":"Pediatr Cardiol"},{"issue":"7","key":"10.1016\/j.hfc.2021.07.012_bib27","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/pace.12878","article-title":"Implantable Cardioverter Defibrillator Outcomes in Pediatric and Congenital Heart Disease: Time to System Revision","volume":"39","author":"Dechert","year":"2016","journal-title":"Pacing Clin Electrophysiol"},{"issue":"2","key":"10.1016\/j.hfc.2021.07.012_bib28","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/hrt.2010.217182","article-title":"The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy","volume":"98","author":"O'Mahony","year":"2012","journal-title":"Heart"},{"issue":"11","key":"10.1016\/j.hfc.2021.07.012_bib29","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1177\/2047487317702519","article-title":"Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: A systematic review and meta-analysis","volume":"24","author":"Norrish","year":"2017","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"10.1016\/j.hfc.2021.07.012_bib30","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00246-015-1298-y","article-title":"Predictors of Long-Term Outcome in Children with Hypertrophic Cardiomyopathy","volume":"37","author":"Ziolkowska","year":"2016","journal-title":"Pediatr Cardiol"},{"issue":"1","key":"10.1016\/j.hfc.2021.07.012_bib31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00246-011-0106-6","article-title":"Restrictive physiology is associated with poor outcomes in children with hypertrophic cardiomyopathy","volume":"33","author":"Maskatia","year":"2012","journal-title":"Pediatr Cardiol"},{"issue":"10","key":"10.1016\/j.hfc.2021.07.012_bib32","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.hrthm.2019.04.040","article-title":"Risk factors for lethal arrhythmic events in children and adolescents with hypertrophic cardiomyopathy and an implantable defibrillator: An international multicenter study","volume":"16","author":"Balaji","year":"2019","journal-title":"Heart Rhythm"},{"issue":"1","key":"10.1016\/j.hfc.2021.07.012_bib33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/CIRCULATIONAHA.117.028895","article-title":"Long-Term Outcomes of Hypertrophic Cardiomyopathy Diagnosed During Childhood: Results From a National Population-Based Study","volume":"138","author":"Alexander","year":"2018","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.hfc.2021.07.012_bib34","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1017\/S1047951105001824","article-title":"Echocardiographic and electrocardiographic identification of those children with hypertrophic cardiomyopathy who should be considered at high-risk of dying suddenly","volume":"15","author":"Ostman-Smith","year":"2005","journal-title":"Cardiol Young"},{"issue":"2","key":"10.1016\/j.hfc.2021.07.012_bib35","doi-asserted-by":"crossref","first-page":"e000658","DOI":"10.1136\/openhrt-2017-000658","article-title":"Predictors of risk for sudden death in childhood hypertrophic cardiomyopathy: the importance of the ECG risk score","volume":"4","author":"Ostman-Smith","year":"2017","journal-title":"Open Heart"},{"key":"10.1016\/j.hfc.2021.07.012_bib36","article-title":"The role of the electrocardiographic phenotype in risk stratification for sudden cardiac death in childhood hypertrophic cardiomyopathy","author":"Norrish","year":"2021","journal-title":"Eur J Prev Cardiol"},{"issue":"8","key":"10.1016\/j.hfc.2021.07.012_bib37","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1161\/CIRCULATIONAHA.117.032966","article-title":"Prevalence and Progression of Late Gadolinium Enhancement in Children and Adolescents with Hypertrophic Cardiomyopathy","volume":"138","author":"Axelsson Raja","year":"2018","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.hfc.2021.07.012_bib38","doi-asserted-by":"crossref","first-page":"E258","DOI":"10.1111\/chd.12286","article-title":"Distribution of Hypertrophy and Late Gadolinium Enhancement in Children and Adolescents with Hypertrophic Cardiomyopathy","volume":"10","author":"Windram","year":"2015","journal-title":"Congenit Heart Dis"},{"issue":"7","key":"10.1016\/j.hfc.2021.07.012_bib39","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.amjcard.2013.12.034","article-title":"Clinical significance of late gadolinium enhancement in patients<20 years of age with hypertrophic cardiomyopathy","volume":"113","author":"Smith","year":"2014","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.hfc.2021.07.012_bib40","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/cge.13157","article-title":"Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy","volume":"93","author":"Mathew","year":"2018","journal-title":"Clin Genet"},{"issue":"6","key":"10.1016\/j.hfc.2021.07.012_bib41","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/jamacardio.2018.0789","article-title":"Long-term Outcomes of Pediatric-Onset Hypertrophic Cardiomyopathy and Age-Specific Risk Factors for Lethal Arrhythmic Events","volume":"3","author":"Maurizi","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"6","key":"10.1016\/j.hfc.2021.07.012_bib42","doi-asserted-by":"crossref","first-page":"e003818","DOI":"10.1161\/CIRCEP.115.003818","article-title":"Inverted U-shaped relation between the risk of sudden cardiac death and maximal left ventricular wall thickness in hypertrophic cardiomyopathy","volume":"9","author":"O'Mahony","year":"2016","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"7","key":"10.1016\/j.hfc.2021.07.012_bib43","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0735-1097(98)00493-8","article-title":"Long-term outcome and prognostic determinants in children with hypertrophic cardiomyopathy","volume":"32","author":"Yetman","year":"1998","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"13","key":"10.1016\/j.hfc.2021.07.012_bib44","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1161\/CIRCULATIONAHA.108.798314","article-title":"Syncope and risk of sudden death in hypertrophic cardiomyopathy","volume":"119","author":"Spirito","year":"2009","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.hfc.2021.07.012_bib45","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0735-1097(00)01003-2","article-title":"Sudden death in hypertrophic cardiomyopathy: identification of high risk patients","volume":"36","author":"Elliott","year":"2000","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.hfc.2021.07.012_bib46","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1093\/europace\/euz118","article-title":"A\u00a0validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy","volume":"21","author":"Norrish","year":"2019","journal-title":"Europace"},{"issue":"12","key":"10.1016\/j.hfc.2021.07.012_bib47","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jcmg.2016.02.031","article-title":"Prognostic Value of LGE-CMR in HCM: A Meta-Analysis","volume":"9","author":"Weng","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"issue":"12","key":"10.1016\/j.hfc.2021.07.012_bib48","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1016\/j.jcmg.2020.06.009","article-title":"LGE for Risk Stratification in Primary Prevention in Children With HCM","volume":"13","author":"Petryka-Mazurkiewicz","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"issue":"14","key":"10.1016\/j.hfc.2021.07.012_bib49","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.hfc.2021.07.012_bib50","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41588-020-00764-0","article-title":"Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity","volume":"53","author":"Harper","year":"2021","journal-title":"Nat Genet"},{"key":"10.1016\/j.hfc.2021.07.012_bib51","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijcard.2017.07.068","article-title":"Cardiac defects, morbidity and mortality in patients affected by RASopathies. CARNET study results","volume":"245","author":"Calcagni","year":"2017","journal-title":"Int J Cardiol"},{"issue":"5","key":"10.1016\/j.hfc.2021.07.012_bib52","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/ajmg.a.32206","article-title":"Genotype-phenotype analysis and natural history of left ventricular hypertrophy in LEOPARD syndrome","volume":"146A","author":"Limongelli","year":"2008","journal-title":"Am J Med Genet A"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713621000817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713621000817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:41:17Z","timestamp":1761554477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713621000817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1551713621000817"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2021.07.012","relation":{},"ISSN":["1551-7136"],"issn-type":[{"value":"1551-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Risk of Sudden Death in Children with Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Heart Failure Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hfc.2021.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}